Recent developments highlight positive clinical trial data for Namodenoson in pancreatic cancer, capital raising activities, and patent allowances expanding the company’s intellectual property portfolio.

• Can-Fite’s Namodenoson achieved its Phase 2a primary safety endpoint in pancreatic cancer, with ongoing survival follow-up, and raised $4 million via warrant inducements in March 2026 [N3].
• The company’s stock surged significantly following positive Phase 2a pancreatic cancer data announcements in early March 2026 [N2][N4].
• Can-Fite received Canadian patent allowance for Namodenoson as an anti-obesity therapy in February 2026 [N5].
• The company secured a Brazilian patent for its A3AR agonists targeting sexual dysfunction treatment in December 2025 [N6].
• D. Boral Capital maintained a buy recommendation on Can-Fite BioPharma in late 2025 [N7][N8].
• The company is enrolling patients in Phase III and Phase IIb studies for Piclidenoson and Namodenoson, with interim data expected in Q2 2027 [S1].

The bull case for Can-Fite centers on its advancing clinical pipeline, with Piclidenoson in Phase III for psoriasis and Namodenoson progressing in Phase III for liver cancer and Phase IIb for MASH. Positive Phase IIa pancreatic cancer data and ongoing survival follow-up add to the clinical validation. Patent allowances in key markets for Namodenoson’s anti-obesity and sexual dysfunction indications expand potential market opportunities. The company’s ability to raise capital through warrant transactions supports continued development. Out-licensing agreements provide potential milestone and royalty revenues. Successful clinical and regulatory milestones could enhance the company’s commercial prospects and partnerships [S1][N2][N3][N4][N5][N6].

The bear case involves the inherent risks of clinical-stage biopharmaceutical development, including the possibility of clinical trial failures or delays, regulatory hurdles, and the uncertainty of achieving commercial approvals. The company’s revenues remain limited and dependent on milestone and licensing payments, which are uncertain and may be subject to withholding taxes. The net losses and ongoing R&D expenses require continued capital raises, which may dilute shareholders. Competition in the biotech sector and the early stage of some preclinical projects add to execution risks. Failure to secure out-licensing deals or regulatory approvals could materially impact financial performance and operations [S1].

Can-Fite’s moat derives from its proprietary small molecule drug candidates targeting the A3 adenosine receptor, a novel mechanism with potential applications in inflammatory diseases and cancers. The company has secured patents in multiple jurisdictions, including recent allowances in Canada and Brazil, which protect its intellectual property. Its out-licensing agreements and collaborations, such as with Vetbiolix, provide additional revenue streams and development support. However, as a clinical-stage biopharma company, its moat is contingent on successful clinical trial outcomes and regulatory approvals, which remain uncertain. The specialized focus on A3AR agonists and the patent portfolio provide some differentiation in a competitive biotech landscape [S1][N5][N6].

• Clinical Development Risk: The success of Can-Fite’s business depends heavily on the outcomes of clinical trials for its drug candidates. Failures or delays in trials could adversely affect the company’s prospects.
• Regulatory Approval Risk: The company has not yet received regulatory approvals for its products, and the timing and success of such approvals are uncertain.
• Financial Risk: Can-Fite has reported net losses and relies on capital raises and milestone payments to fund operations, which may lead to dilution and liquidity challenges.
• Revenue Uncertainty: Revenues are primarily from out-licensing agreements and milestone payments, which are contingent on factors beyond the company’s control and may not materialize.
• Competition and Market Risk: The biopharmaceutical sector is highly competitive, and Can-Fite’s products face competition from other therapies and companies.

• Can-Fite BioPharma Ltd. is a clinical-stage biopharmaceutical company focused on developing small molecule drugs targeting the A3 adenosine receptor for inflammatory and cancer indications [S1].
• The company generates revenues primarily from out-licensing and distribution agreements, including upfront license fees, milestone payments, and potential royalties, though it has not yet recognized sales-based royalties due to lack of regulatory approvals [S1].
• Key product candidates include Piclidenoson and Namodenoson, with Piclidenoson in a Phase III study for psoriasis (COMFORT study) enrolling patients and interim data expected in Q2 2027 [S1].
• Namodenoson is in multiple clinical trials: a Phase III study in hepatocellular carcinoma (LIVERATION) enrolling patients with interim data expected in Q2 2027, a Phase IIb study in MASH enrolling patients, and a completed Phase IIa study in pancreatic cancer which met its primary safety endpoint with ongoing survival follow-up [S1].
• The company has out-licensing agreements such as with Vetbiolix for Piclidenoson in veterinary osteoarthritis, which includes upfront and milestone payments and royalties upon regulatory approval [S1].
• Research and development expenses were $6.69 million for the year ended December 31, 2025, primarily related to ongoing clinical trials of Piclidenoson and Namodenoson, reflecting an increase from prior years [S1].
• General and administrative expenses were $3.66 million for the year ended December 31, 2025, with increases due to investor relations activities [S1].
• Revenues for the year ended December 31, 2025 were $0.41 million, a decrease from prior years, mainly due to lower recognition of advance payments under distribution agreements [S1].
• As of December 31, 2025, the company had $5.53 million in cash and cash equivalents, $9.44 million in current assets, and $2.73 million in current liabilities, resulting in a current ratio of 3.46 and a cash ratio of 2.02, indicating liquidity adequacy [S1].
• The company has raised capital through public offerings and warrant inducement transactions, including approximately $4.3 million gross proceeds in March 2026 [S1].
• The company’s accounting policies include revenue recognition under ASC 606 and share-based compensation under ASC 718, with critical estimates related to deferred revenue and stock-based compensation [S1].
• Recent news highlights include positive Phase IIa pancreatic cancer data for Namodenoson, leading to stock price surges, and a $4 million capital raise via warrants [N2][N3][N4].
• The company received Canadian patent allowance for Namodenoson as an anti-obesity therapy and a Brazilian patent for its A3AR agonists for sexual dysfunction treatment [N5][N6].
• D. Boral Capital maintained a buy recommendation on Can-Fite BioPharma in late 2025 [N7][N8].